Alcohol-related hepatocellular carcinoma (HCC) develops with advanced alcoholic liver disease and liver fibrosis. Using adult mice, we evaluate the effect of alcoholic steatohepatitis on early hepatobiliary carcinoma after initiation by diethyl-nitrosamine (DEN). Here we show that alcohol-fed DEN-injected mice have higher ALT and liver-to-body weight ratio compared to pair-fed DEN-injected mice...

AIM To investigate the natural history of patients with non-alcoholic steatohepatitis by means of a prospective histological study. METHODS One thousand five hundred and seventy one patients underwent liver biopsy at the Western Infirmary in Glasgow during the 10 year period 1985 to 1994. All biopsies were reported by a single pathologist: 62 were confirmed as having non-alcoholic steatohepat...

ALTHOUGH its histological features had long been recognized (1). the term non-alcoholic steatohepatitis (NASH) was first used by Ludwig et al. as recently as 1980 (2). Although it is commonly encountered in hepatology outpatient (office) practice (3). surprisingly little attention has been paid to NASH. It will be the purpose of this review to examine the clinical and pathological features of N...

BACKGROUND AND AIM Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease worldwide, with a prevalence of 20%-40% in Western populations. The purpose of this article is to review data related to lifestyle changes in patients with NAFLD. METHOD We searched a public domain database (PubMed) with the following categories: disease (NAFLD, fatty liver, and non-alcoholi...

Non-alcoholic fatty liver disease (NAFLD) may be present as simple steatosis and progress to non-alcoholic steatohepatitis (NASH). This inflammation of the liver tissue is a prerequisite to hepatic fibrosis and cirrhosis. NAFLD represents an important and common cause of liver disease worldwide. It is commonly associated with other medical problems such as obesity, cardiovascular disease, diabe...

It has come to our attention that the excel files of following supplementary tables were not included during online publication article: Table S3, S4, S8, S9, S13, and S14. These have now been made available online. We apologize for any inconvenience caused. Molecular characterisation hepatocellular carcinoma in patients with non-alcoholic steatohepatitisJournal HepatologyVol. 75Issue 4PreviewN...

The former is a sequel of acute viral hepatitis A and B, toxic hepatitis as a result of severe poisoning with hazardous substances or rapid blockage of the liver blood supply, while the latter one is an after-effect of chronic hepatitis B, C and autoimmune hepatitis, longterm alcohol abuse, disordered bile outflow, certain drugs administration, non-alcoholic fatty liver disease (NAFLD) and non-...

PETACH TIKVA, Israel, May 3, 2017 /PRNewswire/ -Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today provided an update on a Phase II clinical trial to evaluate its liver drug candidate Namodenoson (CF102) in the treatment of non-alcoholic fatty liver disease...

Non-alcoholic fatty liver disease has become one of the most common causes of chronic liver disease that can develop into a more serious form, non-alcoholic steatohepatitis, leading to liver cirrhosis and hepatocellular carcinoma. Although hepatic retinoid stores are progressively lost during the development of liver disease, how this affects steatohepatitis and its related hepatocarcinogenesis...

Excess alcohol consumption and the associated development of alcoholic liver disease (ALD) are major public health challenges worldwide. Since patients with the severe stages of ALD no longer benefit from clinical therapies, early warning of ALD holds significant promise for increasing the cure rate of ALD. Herein, we develop a bicolor fluorescent nanoprobe for dynamically monitoring the conver...